Zoster Treatment Market - Growth Drivers and Challenges
Growth Drivers
-
Growing government spending on zoster therapeutics: In the U.S., Medicare has spent on herpes zoster antiviral drugs in 2023 that has reached over USD 1.7 billion, which is an 18.4% rise since 2020. This rise is due to the improved vaccination access and high-quality treatment for elderly people. The average per capita cost for Medicare-covered persons getting zoster-related drugs was USD 326.6 per year, demonstrating a significant public investment in long-term illness prevention and management.
-
Early intervention reducing hospitalization rates: As per the report from AHRQ, administering antiviral drugs within 72 hours has resulted in a minimization in hospital admissions for postherpetic neuralgia, resulting in healthcare savings of USD 382.9 million in the past two years. The report finally supports incorporating the timely antiviral treatment into healthcare quality improvement programs to provide fewer complications and associated costs.
Historical Patient Growth & Its Impact on Zoster Treatment Market Dynamics
Historical Patient Growth (2010-2020) in Key Markets
|
Country |
2010 Patient Count (Million) |
2020 Patient Count (Million) |
Growth (%) |
|
U.S. |
1.1 |
1.6 |
38.7% |
|
Germany |
0.7 |
0.9 |
44.2% |
|
France |
0.9 |
0.8 |
43.8% |
|
Spain |
0.6 |
0.9 |
50.5% |
|
Australia |
0.4 |
0.6 |
63.9% |
|
Japan |
1.2 |
1.5 |
31.8% |
|
India |
1.1 |
1.4 |
72.5% |
|
China |
1.7 |
2.8 |
67.9% |
Strategic Expansion Models Driving Revenue Feasibility in the Zoster Treatment Market
Feasibility Models for Revenue Growth
|
Country |
Expansion Model |
Revenue Growth (2022–2024) |
Key Driver |
|
India |
Public-private partnerships with regional clinics & pharma |
+12.4% |
High burden of untreated elderly; low-cost antiviral demand; MoHFW vaccination push |
|
USA |
Medicare Part D shingles coverage expansion |
+16.9% |
Aging population; FDA Shingrix labeling extension; Medicare support for zoster antivirals |
|
Japan |
Domestic API manufacturing + regional drug subsidies |
+9.8% |
Government incentives for local drug sourcing; improved generic antiviral accessibility |
|
Germany |
Hospital-led early treatment incentives under public insurance |
+10.5% |
National insurance funds covering antiviral cost if initiated within 72 hours |
|
France |
Integrated treatment-vaccine bundling in elder care facilities |
+9.2% |
State reimbursement for bundled zoster care packages in public hospitals |
|
China |
Tier 2–3 city e-pharmacy + chain hospital supply partnerships |
+14.6% |
Mass aging population; digital prescription expansion in rural provinces |
|
Australia |
Medicare-backed shingles management programs in aged care |
+11.8% |
Federal program support for vaccine and treatment for citizens aged 70+ |
Challenges
-
Government-imposed pricing caps: The EU government has maintained a strict reimbursement on zoster treatments, minimizing the broader market access. EU countries such as France and Germany applied strong reimbursement limits on zoster therapies, resulting in restricted access. GSK, for instance, collaborated with national health authorities to roll out bundled care schemes integrating its Shingrix vaccine with antiviral treatments under programs of elderly care programs. This approach complemented population health objectives and stayed within spending limits, enabling wider patient coverage. Consequently, GSK increased Zoster treatment availability by about 10.6% in each country while complying with government reimbursement restrictions.
Zoster Treatment Market Size and Forecast:
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
6.5% |
|
Base Year Market Size (2024) |
USD 6.5 billion |
|
Forecast Year Market Size (2037) |
USD 14.2 billion |
|
Regional Scope |
|
